Operational Update
The Company has been under a failure to file cease trade order (“FFCTO”) since April 8, 2024. - FACT and a pathetic one! totally pathetic. Thank you Trippy
During the period of April to October, 2024, the Company undertook several, significant improvements to its operations that are anticipated to increase effectiveness as well as significantly reduce costs:
- the lab in Richmond has relocated to a smaller, more functional space with an approximate 70% reduction in costs. It is fully operational again; - what this means is that we never had enough buisness to run that other lab cause we have no clients. Our management team were complete morons for thinking we could actually utilize a bigger space for anything other than renting most of it out to another company that actually knows what they are doing.
- CareOncology UK has been focussed strongly into Europe (population 780 million) with the addition of clinicians based in Europe, offering service in local languages, and operations realigned to support an expanded clinical support group with nurses, nurse practitioners, prescribing pharmacists, nutritionists and clinicians; - oh so Europe has that many people huh? must be a guarentee of sucess right? how many people live in the USA? how long as Genenews/Stagezero been at it in the USA? lots of revenue eh? no stock halt for 8 months cause they cant pay one auditor bill?? how is this different from what CARE has been doing long before Stagezero bought them?? Same BS wrapped up with even less substance.
- CareOncology UK/Europe continues to service multiple countries worldwide eg Australia, New Zealand, India and is exploring offering the COC Protocol to patients in Arabic speaking countries with local clinicians; - Tripps new plan "hey lets send an email or two to a couple new countries and tell our sucker investors that we have trapped with a halted stock for the last 8 months that we "service" these countries. hahah they will believe anything i say just like when I invented Oncore! ahahahaha
- CareOncology USA, which serves both the US and Canada, is being focussed strongly into supporting AVRT with employers and “at risk” individuals and will add clinical staff to provide services to all US States and all of Canada. Significant process improvements have been put in place to increase the level of patient support and minimize costs. - AVRT which has made how much money? how many paitients have gone through AVRT? we will never know because Stagezero shares just so much info with their investors. Its hard to track number of paitients so hard. Especially when you dont know how to pay auditors
- After relocation of the lab, Aristotle is being introduced to patients by several new partners. As the lab scales to full capacity, it is anticipated that revenue growth will increase commensurately. - several new partners eh? jee wiz how many times have we heard the same bs from this company? When has there ever been any partners that made this company any money? such an important test, better than Grail yet no one gives a care. Do you think Rebecca's grandma counts as a partner because she told her friends about the cancer test her granddaughter is a part of? They add this same lie in everything they say for the past 5 years. Remember come for covid stay for cancer. But when it comes to the covid excuse Stagezero still thinks they just came out of covid.
Revenues for Q3 are showing an increase over Q2 as operations normalize. The first half of 2024 saw a decrease in revenues due to operational changes; revenues began to recover in Q3 and, with the scale up in Aristotle testing, are expected to ramp through the next twelve months. Additionally, the approximately 50% decrease in total operating costs are primarily due to the changes made to the Company to improve costs and operational effectiveness. - you know those operational changes like shutting down the last lab they talked so highly about and moving to another location and being so TRANSPARENT to their investors that we werent told they were doing it at all? More lies from Tripp and this company. Keep investors in the dark
The Company is diligently continuing its efforts to have sufficient funds to fully pay the auditors. It anticipates having them paid by December 31st, 2024. An application has been made to the OSC for a partial revocation of the FFCTO. The partial revocation would be needed to allow for a possible equity transaction with the specific purpose of filing the 2023 year end financials and associated documents, and then applying for a full revocation of the FFCTO. Funding could come in the form of an equity transaction, or as a debt transaction. The Company will update the market as required and once agreements have been concluded. - still cant get the money together to pay a few auditors a payment we knew we had to make every year. Why cant we pay it? Well we pay our ceo far too much money and the last CFO we had didnt buy our BS and sued us for not paying him so a court had to force us to pay him so now we dont have any money. oh and we put a date of Dec 31 cause everyone will be thinking of xmas and we think so low of our investors we assume no one will notice when we dont meet yet another deadline we gave ourselves. Oh and just in case you do notice we put that little thing in there about contacting the FFTCO so that when we dont meet our deadline and another couple months goes by we can say it wasnt our fault but that of the FFTCO.
Q3 2024 Financial Results
The Company generated $1.412 million in cancer testing and treatment revenue for the nine months ended September 30, 2024 as compared to revenue of $2.206 million for the nine months ended September 30, 2023 and realized a net loss of $1.435 million, or $0.01 basic and diluted loss per common share as compared to a $3.035 million net loss for the nine months ended September 30, 2023, or $0.03 basic and diluted loss per common share.
The Company generated $0.500 million in revenue for the three months ended September 30, 2024 as compared to revenue of $0.745 million for the three months ended September 30, 2023 and realized a net loss of $0.399 million, or $0.00 basic and diluted loss per common share as compared to $0.822 million net loss for the three months ended September 30, 2023, or $0.01 basic and diluted loss per common share. - basically our company is failing because of our worthless overpaid ceo and the only way to keep getting him paid for alittle longer was to decrease our costs but going to a small lab and laying off workers. Tripp needs his money that is #1 priorty for Stagezero and we feel our investors want that too. The next step will be for us to lay everyone off and try to sublease our new smaller lab out to another company that actually knows how to make money and not cheat their investors out of their money.